CG-806 (Luxeptinib) (Synonyms: CG-806) |
رقم الكتالوجGC33064 |
CG-806 (Luxeptinib) (CG-806) هو مثبط فعّال شفوياً ، وقابل للعكس ، وهو الأول في فئته ، وغير تساهمي وقوي ، ومثبط Pan-FLT3 / pan-BTK. يحث CG-806 (Luxeptinib) على إيقاف دورة الخلية أو موت الخلايا المبرمج أو الالتهام الذاتي في خلايا سرطان الدم النخاعي الحاد.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1616428-23-9
Sample solution is provided at 25 µL, 10mM.
CG-806 is a pan FLT3/BTK Multi-Kinase inhibitor.
CG-806 (CG'806) is a small molecule multi-kinase inhibitor against FLT3 and BTK kinases that is under development to treat FLT3-driven AML. CG-806 exerts potent picomolar IC50 anti-proliferative activity against human AML cells and against Ba/F3 mouse AML cells with FLT3-ITD mutations (about 50 to 250-fold higher activity compared to quizartinib or gilteritinib). Specifically, compared to second-generation FLT3 inhibitors quizartinib or gilteritinib, CG-806 shows much more pronounced anti-proliferative effects in leukemia cells with D835 mutations, the ITD plus F691L/Y842D/D835 mutations, or in FLT3 wild-type cells (IC50s are 0.17, 0.82, 9.49, 0.30, 8.26, 9.72, and 0.43 nM for human ITD-mutated AML cells MV4-11, MOLM13, murine ITD mutated leukemia cells Ba/F3 WT, Ba/F3-ITD, Ba/F3-D835Y, Ba/FLT3-ITD+D835Y, and "gatekeeper" mutation Ba/F3-ITD+F691L cells, respectively). Furthermore, CG-8066 triggers profound apoptosis in cell lines. Mechanistically, CG-806 profoundly suppresses FLT3 and its downstream MAPK/AKT signaling, as well as phospho-Aurora, and/or phospho-BTK proteins, suggesting the ability of CG-806 to inhibit various kinases that function in AML signaling and appear to contribute to its effectiveness[1].
CG-806 demonstrates in vivo tumor eradication without toxicity when administered orally, once daily for 14 d as a single agent in the MV4:11 AML murine xenograft model, and demonstrates sustained micromolar plasma drug levels in mice after a single oral administration. CG-806 can be considered not only a pan-FLT3 inhibitor for targeting FLT3 wild type and ITD-mutant AML, but also a one-of-a-kind agent killing leukemia cells with TKD or dual TKD plus ITD mutations, which are frequently associated with resistance/relapse in FLT3-mutant AML patients. CG-806 exerts a robust therapeutic window in animal xenograft studies. Thus, CG-806 warrants further investigation for the treatment of newly diagnosed and relapsed/refractory patients with FLT3-mutated AML[1].
[1]. Weiguo Zhang, et al. CG0806, a First-in-Class FLT3/BTK Inhibitor, Exerts Superior Potency against AML Cells Harboring ITD, TKD and Gatekeeper Mutated FLT3 or Wild-Type FLT3.
Average Rating: 5
(Based on Reviews and 40 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *